A Prospective Placebo Controlled Study Comparing Silodosin Versus Tadalafil Versus the Combination of Silodosin and Tadalafil as a Medical Expulsive Therapy for Lower Third Ureteric Stones.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202506759440037

Enrollment

176

Registered

2025-06-19

Start date

2025-07-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological and Genital Diseases

Interventions

Placebo

silodosin

Tadalafil

Combined sildosin 8mg and tadalafil 5mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Adult patients aged 18 years or older who presented to the Urology Department with - single ureteral stone less than 1cm in size. - located in the distal ureter. - Ability to provide informed consent and comply with study requirement.

Exclusion criteria

Exclusion criteria: 1-Patients with active urinary tract infection. 2- Severe refractory pain. 3-Severe hydronephrosis according to onen classification . 4- Acute or chronic renal failure. 5-Multiple ureteral stones. 6- Bilateral ureteral calculus. 7- Single functioning kidney. 8- Any history of ureteral surgery or procedure. 9- Urinary tract anomalies. 10-Patients receiving concomitant treatment with alpha-blockers calcium channel blockers, nitrates, steroids, or PDE5. 11- Pregnant or Lactating mother or Uncontrolled hypertension. 12- Patients who demanded urgent stone removal were also not included.

Design outcomes

Primary

Measure	Time frame
Stone expulsion rate	—

Secondary

Measure	Time frame
Stone expulsion time.;Number of colicky attacks.;Analgesics required.;Drug side effects	—

Countries

Egypt

Contacts

Public ContactMohamed Radwan

Professor of Urology at Tanta University

drradwan@yahoo.com00201006714078

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026